Clinical Trial

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study was an open-label phase I study to evaluate the safety, tolerability, PK profile and potential efficacy of SSGJ-705 as a single agent in patients with advanced malignancies.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-24.
Trial Details
NCT Number NCT06390774
Lead Sponsor Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Conditions Locally Advanced, Recurrent or Metastatic Malignancies
Enrollment 180 participants
Start Date 2024-05-30
Primary Completion 2026-12 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2024-10-18